As with other checkpoint molecules, including LAG-3 (73) and TIGIT (75), combination therapies blocking TIM-3 in combination with PD-1 exhibited synergistic effects in preclinical tumor models (74, 101). Here, HAVCR2 is linked to neoplasm.